MOUNTAIN VIEW, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that it will host its third quarter 2025 financial results and business highlights conference call on November 13, 2025, at 4:30 p.m. ET. Additional details will be available on the Investor Relations section of the Company’s we ...

Leading Expert on Targeted Drug-Delivery and Locoregional Cancer Therapies Strengthens RenovoRx’s Scientific Advisory BoardLOS ALTOS, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced the appointment of renowned interventional oncologist Thierry de Baère, MD, PhD to RenovoRx’s Scientific Advi ...

Summary of RenovoRx Conference Call Company Overview - **Company**: RenovoRx (NasdaqCM:RNXT) - **Industry**: Medical Technology, specifically focused on cancer treatment and drug-device combinations Key Points and Arguments 1. **Advancements in Cancer Care**: RenovoRx is advancing medicine through innovative technologies aimed at reducing toxicity in cancer treatments while effectively targeting tumors [2][3] 2. **RenovoCath Device**: The FDA-cleared RenovoCath device has been commercialized, with revenues in the first half of the year exceeding expectations despite having no sales force in place [3][4] 3. **Market Opportunity**: The initial market opportunity for the RenovoCath device is estimated at $400 million, with potential for significant growth as the device is used in various cancer treatments [4][13] 4. **Clinical Trials**: The TIGeR-PaC phase III trial is focused on treating locally advanced pancreatic cancer, with enrollment nearing completion [4][16] 5. **Mechanism of Action**: The RenovoCath device utilizes Transarterial Microperfusion (TAMP) to deliver chemotherapy directly to tumors, particularly those that are hypovascular and resistant to systemic treatments [5][6][12] 6. **Patient Experience**: The treatment procedure is outpatient, takes about 90 minutes, and does not require general anesthesia, leading to a better quality of life for patients [10][11] 7. **Survival Benefits**: Interim analysis from the TIGeR-PaC trial shows a six-month survival benefit for patients treated with the RenovoCath device compared to standard treatments, along with a 65% reduction in adverse events [22][23] 8. **Commercial Strategy**: RenovoRx plans to expand its commercial efforts with a small, efficient sales team targeting high-volume surgical centers and academic institutions [15][16] 9. **Financial Health**: The company reported $600,000 in revenue in the first half of the year and has a cash reserve of $12.3 million, which is expected to last into late 2026 [16][28] 10. **Patent Protection**: RenovoRx holds over 19 issued patents worldwide, ensuring protection for its technology and innovations [14] Additional Important Content 1. **Future Trials and Indications**: There is interest in expanding the use of the RenovoCath device to other cancers, including cholangiocarcinoma and non-small cell lung cancer [30][32] 2. **Metrics for Commercial Traction**: The company is focusing on the number of centers approved to use the device and the volume of patients treated, rather than just revenue figures [32][33] 3. **Partnership Opportunities**: RenovoRx is in discussions with potential partners, including Boston Scientific, to scale commercial efforts and explore acquisition possibilities [37][39] 4. **Regulatory Pathway**: The company anticipates engaging with the FDA for an accelerated approval pathway based on the positive survival and safety signals from the TIGeR-PaC trial [40] This summary encapsulates the key insights from the RenovoRx conference call, highlighting the company's innovative approach to cancer treatment, market potential, and strategic plans for growth and commercialization.

Core Viewpoint - RenovoRx, Inc. is actively commercializing its FDA-cleared drug-delivery device, RenovoCath, and is presenting at the iAccess Alpha Virtual Best Ideas Fall Investment Conference to discuss its commercialization efforts and ongoing clinical trials [1][2][3] Company Overview - RenovoRx, Inc. is a life sciences company focused on developing targeted oncology therapies and commercializing RenovoCath, a patented drug-delivery device that addresses high unmet medical needs [6] - The company utilizes its Trans-Arterial Micro-Perfusion (TAMP™) therapy platform for targeted therapeutic delivery, aiming to improve safety and efficacy compared to traditional systemic therapies [6] Commercialization Efforts - The company has received its first commercial purchase orders for RenovoCath devices as of December 2024, with several customers initiating repeat orders [9] - RenovoRx is expanding its customer base, including high-volume National Cancer Institute-designated centers, to meet anticipated demand for RenovoCath [10] Clinical Trials - The ongoing Phase III TIGeR-PaC clinical trial is evaluating the intra-arterial gemcitabine delivered via RenovoCath for treating locally advanced pancreatic cancer (LAPC) [3][7] - The Data Monitoring Committee has recommended continuing the trial after reviewing a second pre-planned interim analysis triggered by 52 deaths [3] Product Information - RenovoCath is designed for isolating blood flow and delivering fluids to specific sites in the peripheral vascular system, with applications including temporary vessel occlusion and chemotherapeutic drug infusion [5] - The combination product candidate, IAG, which uses RenovoCath, has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [8]

Core Viewpoint - Biotech stocks are experiencing renewed momentum, with small-cap companies like Nautilus Biotechnology, PepGen, Lixte, RenovoRx, Genelux, and VolitionRx attracting investor interest through various catalysts such as insider buying, strategic partnerships, and clinical trial progress Group 1: Nautilus Biotechnology (NAUT) - Nautilus Biotechnology's stock surged 5.52% during regular trading, closing at $0.7070, and rose an additional 7.5% in after-hours trading to $0.76, with trading volume nearly double its average at 647,399 shares [2] - Recent insider buying by CEO Sujal M. Patel, who purchased 83,500 shares on September 8 and 116,500 shares on September 5, totaling over $135,000, indicates strong leadership confidence [3] - The company reported a narrower loss of $0.12 per share in Q2 2025, with an 18% drop in operating expenses, and has $179.5 million in cash, providing a financial runway through 2027 [4] Group 2: PepGen Inc. (PEPG) - PepGen's stock rebounded 7.14% in after-hours trading to $1.50 after a regular session close of $1.40, with trading volume more than double its average at 638,576 shares [4] - The company completed dosing for its 15 mg/kg arm of the FREEDOM trial, with topline data expected in early Q4 2025, following a strategic narrowing of its pipeline [5] Group 3: Lixte Biotechnology Holdings Inc. (LIXT) - Lixte's stock rose 5.85% in after-hours trading to $5.25 after closing at $4.96, with a trading volume of 503,604 shares, notable given recent volatility [5] - The company announced a $2.6 million purchase of Bitcoin and Ethereum to diversify its treasury holdings, reflecting a strategic shift in financial strategy [6] Group 4: RenovoRx Inc. (RNXT) - RenovoRx shares increased 4.22% in after-hours trading to $1.2194 after a regular session close of $1.17, with trading volume significantly above its average at 886,119 shares [6] - The company received a positive recommendation to continue its Phase III TIGeR-PaC trial for pancreatic cancer, reinforcing confidence in its lead therapy platform [7] Group 5: Genelux Corp. (GNLX) - Genelux's stock rose 4.11% in after-hours trading to $3.80 after closing at $3.65, with trading volume relatively light at 60,339 shares [8] - The recent activity follows Genelux's participation in the H.C. Wainwright Global Investment Conference [9] Group 6: VolitionRx Ltd. (VNRX) - VolitionRx's stock increased 4.27% in after-hours trading to $0.6474 after closing at $0.6209, with trading volume slightly below its average at 183,777 shares [10] - The company announced a Research License and Exclusive Commercial Option Rights Agreement with Werfen's Immunoassay Technology Center, focusing on advancing its Nu.Q NETs assay for Antiphospholipid Syndrome [10]

Core Insights - RenovoRx has expanded its commercial footprint to thirteen cancer centers approved to purchase its RenovoCath device, a significant increase from five centers in Q1 2025 [2][3] - The company has hired Philip Stocton as Senior Director of Sales and Market Development to enhance its commercialization strategy [4][6] - There is a growing clinical demand for localized solid tumor drug-delivery options, indicating a positive market trend for RenovoRx's offerings [3][5] Company Developments - Since launching commercial efforts in December 2024, RenovoRx has established a customer base of thirteen cancer centers, with four actively using RenovoCath and placing repeat orders [2][11] - The hiring of Philip Stocton, who has over 25 years of experience in MedTech sales, is expected to drive the company's commercialization efforts [4][6] - The company is focused on building sales momentum without significant capital outlays, indicating a strategic approach to growth [6] Product Information - RenovoCath is an FDA-cleared drug-delivery device designed for targeted therapeutic delivery, aiming to minimize systemic toxicity compared to traditional chemotherapy methods [8][9] - The device is currently being evaluated in the ongoing Phase III TIGeR-PaC trial, which could lead to additional customer acquisition post-enrollment completion [3][9] - RenovoRx's TAMP therapy platform, enabled by RenovoCath, aims to improve safety and efficacy for cancer patients [8][10]

Summary of RenovoRx (RNXT) Conference Call - May 21, 2025 Company Overview - RenovoRx specializes in localized chemotherapy delivery through its patented device, RenovoCath, which utilizes a method called transarterial microperfusion (TAMP) [1][2] - The company has received orphan drug designation for its drug-device combination product in two indications, with a focus on pancreatic and bile duct cancers [2][20] Core Points and Arguments - **Commercialization and Revenue Generation**: RenovoRx has begun commercializing its device, generating approximately $200,000 in revenue during its first full quarter of sales [15][18] - **Market Potential**: The potential peak revenue for the device in the U.S. is estimated at $400 million, with an initial target market of around 7,000 patients [3][6] - **Clinical Trials**: The company is conducting a pivotal phase three trial (TIGER PACT) for its drug-device combination, with positive interim results indicating a 65% reduction in side effects compared to traditional systemic chemotherapy [23][29] - **Physician Interest**: There is significant inbound interest from physicians, particularly for treating patients with pancreatic cancer, as the device offers a less toxic alternative to traditional chemotherapy [11][12][14] Financial and Growth Strategy - **Sales Strategy**: RenovoRx plans to leverage a small sales team to target approximately 200 high-volume cancer treatment centers in the U.S., minimizing the need for a large sales force [7][18] - **Revenue Growth Potential**: Each patient treated could represent multiple device sales, with potential revenues ranging from $6,000 to $9,000 per device, leading to significant revenue growth opportunities [17][18] - **Funding Research and Development**: The revenue from the catheter sales is expected to fund ongoing research and development activities, potentially leading to cash flow positivity [21][18] Clinical and Competitive Advantages - **Reduced Side Effects**: The localized delivery mechanism significantly reduces systemic side effects associated with traditional chemotherapy, improving patient quality of life [23][24] - **Survival Benefits**: Early data from trials suggest that patients may experience longer survival rates due to the effective delivery of chemotherapy directly to tumors [25][29] Upcoming Catalysts - **Second Interim Analysis**: The second interim analysis of the TIGER PACT trial is expected in the third quarter of 2025, which will provide further insights into the trial's progress and potential outcomes [30][32] - **Insider Confidence**: Management has shown confidence in the company's future by purchasing shares in the open market, indicating belief in the company's undervaluation [34] Additional Insights - **Market Positioning**: RenovoRx is positioned favorably compared to analogs like Delcath and NovoCure, with management believing the company is undervalued in the current market [34] - **Optionality in Strategy**: The company has the flexibility to pivot between focusing on catheter sales or advancing drug-device combinations based on market conditions and trial outcomes [22]

RenovoRx Investment Highlights - RenovoRx is developing combination therapies based on its proprietary Trans-Arterial Micro-Perfusion (TAMP) platform[4] - The FDA granted Orphan Drug Designation to RenovoRx's lead device/drug combination product candidate (RenovoCath plus Gemcitabine) in pancreatic and bile duct cancers[4] - RenovoCath, an FDA 510(k) cleared device, is being commercialized with first purchase orders received in Q4 2024[4] - RenovoRx anticipates initial revenues from RenovoCath in Q1 2025[45] TIGeR-PaC Phase III Clinical Trial - RenovoRx is advancing its pivotal Phase III TIGeR-PaC study for the treatment of locally advanced pancreatic cancer (LAPC)[5] - The first interim analysis of the TIGeR-PaC study showed a 65% reduction in adverse effects[5] - The second interim analysis of the TIGeR-PaC study is anticipated by the end of 1H 2025[5, 63] Market Opportunity - RenovoRx is pursuing a ~$400 million potential peak annual United States revenue opportunity for RenovoCath with initial clinical interest[5] - The company sees an opportunity to expand potential RenovoCath indications of use and estimated total addressable market for RenovoCath to several billion dollars with patent protection to 2038[5, 35] - Approximately 67,000 patients across areas of expressed interest in the US could benefit from RenovoCath[40]